Sasquatch Researcher Says Bigfoot Ravaged Apple Orchard in his Backyard?
Sasquatch Researcher Says Bigfoot Ravaged Apple Orchard in his Backyard? Like or Follow at ... http://www.facebook.com http://www.twitter.com #mothershouldi A Vermont man insists he spotted Bigfoot in his backyard -- and he says he #39;s got video to prove it. Frank Siecienski of Hubbarton first thought that it was only a deer ravaging the apple orchard that stands on his property last year. "I pointed it out to my wife and she says #39;oh God, #39; the deer must have been hungry," he told WCAX-TV this April. "And I said no, a deer couldn #39;t have eaten that many apples in one night." So the self-described Sasquatch researcher set up a camera to keep watch of what was going on outside. http://www.nydailynews.com I find it suspicious that he is a Sasquatch researcher, and discovers a Sasquatch on his own property.This video was posted on 11/25/2012. Then, today (11/26/2012), I find this article: #39;Bigfoot #39; DNA Sequenced In Upcoming Genetics Study http://www.prweb.com This video uses copyrighted material in a manner that does not require approval of the copyright holder. It is a fair use under copyright law.Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for fair use for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use.From:MotherShouldIViews:0 0ratingsTime:01:25More inEducation

Link:
Sasquatch Researcher Says Bigfoot Ravaged Apple Orchard in his Backyard? - Video

Recommendation and review posted by Bethany Smith

DNA Genetics At the 25th Cannabis cup
From:ShrillMillViews:3 0ratingsTime:21:50More inGaming

Continue reading here:
DNA Genetics At the 25th Cannabis cup - Video

Recommendation and review posted by Bethany Smith

External Thrombosed Hemorrhoids and What You Can Do Today
http://www.HemRid.com External Thrombosed Hemorrhoids and What You Can Do What are external thrombosed hemorrhoids and how can you get fast and powerful relief? External thrombosed hemorrhoids occur when an external hemorrhoids becomes strangulated. The hemorrhoid will form a clot because the blood pools within the hemorrhoid as a result of being strangulated. Diet and exercise play a key role in how likely and often you will have hemorrhoids. Age, pregnancy, and genetics are also factors too. If you think that you may have hemorrhoids you should consult your doctor. http Please visit http://www.HemRid.com for more information on external thrombosed hemorrhoids surgery, external thrombosed hemorrhoids removal, external thrombosed hemorrhoids treatment, and external thrombosed hemorrhoids symptoms.From:hemridvideosViews:2 0ratingsTime:01:42More inEducation

See more here:
External Thrombosed Hemorrhoids and What You Can Do Today - Video

Recommendation and review posted by Bethany Smith

BAMF Bombs in Amsterdam High Times Cannabis Cup
The PotCast visits Amsterdam for the 25th High Times Cup. They are gathered at the Cali Connection booth dabbing on some Solventless Lemon Og made by BAMF of BAMF Extractions and Selecta Nikka T from Essential Extractions. West Coast Concentrates, MTG Seeds, Rare Dankness, DabTools, The Digger, OG Genetics were also on scene. Check out this epic moment in PotCast history! PC420.comFrom:stingystonerViews:3 2ratingsTime:03:42More inComedy

View post:
BAMF Bombs in Amsterdam High Times Cannabis Cup - Video

Recommendation and review posted by Bethany Smith

Newswise BETHESDA, MD -- November 26, 2012 -- The Genetics Society of America (GSA) is pleased to announce the selection of two early career scientists, graduate student Kathleen Dumas (University of Michigan, Ann Arbor) and postdoctoral researcher Krista Dobi, PhD (Memorial Sloan-Kettering Cancer Center, New York), as advisory representatives to the GSA Board of Directors. These two individuals were selected from among more than 50 of GSAs graduate student and postdoctoral members who volunteered to serve in leadership positions on the GSA Board of Directors. Additional early career researchers will be selected to contribute to the work of GSA committees.

GSA has a long history of supporting its early career members through programs and policies that promote the professional development of our student and postdoc members, said GSA President Phil Hieter, PhD. The selection of Kathleen and Kristaand their peers on our committeeswill ensure that the next generation of geneticists will always be at the table when Society priorities are discussed.

GSA Executive Director Adam Fagen, PhD, added that we hope this is just the beginning of more active engagement of our early career members in the work of the Society. Students and postdoctoral scholars represent nearly half of GSAs 5,000 members.

Ms. Dumas is a graduate student in the Cell and Molecular Biology Department at the University of Michigan (UM), Ann Arbor, working on insulin signaling genetics in the nematode worm C. elegans and also completed a graduate certificate program in Science, Technology, and Public Policy. Her research success has been facilitated by what she expressed as the collaborative environment among C. elegans researchers. Ms. Dumas has a history of volunteer service to her professional community, which includes serving as co-president of the Graduate Student Council at UM; revitalizing a moribund chapter of the Association for Women in Science; and serving as a lead organizer for a forum for graduate students and postdoctoral fellows to share research, gain interdisciplinary perspectives and network with experts in the science and policy fields. Ms. Dumas has attended several International C. elegans meetings organized by GSA and received a 2012 GSA DeLill Nasser Travel Award for Professional Development in Genetics.

Katie Dumas is a sophisticated student researcher who has exceptional leadership skills and dedication to bridging the interface between research and public policy, said Jessica Schwartz, PhD, Director of the PhD Program in Cell & Molecular Biology at UM. She is an excellent communicator and will represent an informed student perspective effectively. I am certain that Katie will make excellent contributions to GSA, she added.

I am honored and excited to serve as the inaugural advisory graduate student representative to the GSA Board of Directors, said Ms. Dumas. I believe the Societys commitment to embracing the perspectives of its graduate student constituents exemplifies its mission to support the next generation of geneticists.

Dr. Dobi, a postdoctoral researcher in developmental biology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, is studying the development of muscles in the fruit fly Drosophila melanogaster. As a graduate student she studied gene regulation in the yeast Saccharomyces cerevisiae. Not only does she have varied and rich research experiences, according to her MSKCC postdoctoral mentor Mary Baylies, PhD, Dr. Dobi is an effective and clear communicator, an excellent mentor, and she has excellent organizational and leadership abilities. She has mentored high school, undergraduate and graduate students, served on advisory committees and organized conferences. While an undergraduate at Princeton, she also served as executive director of the Princeton Model Congress, planning a conference in Washington, D.C. for 1,000 high school students and their teachers. Dr. Dobi has attended GSA-sponsored Drosophila research conferences and received a 2012 GSA DeLill Nasser Travel Award for Professional Development in Genetics.

As a yeast and Drosophila geneticist, I am truly honored to be the first postdoctoral representative to the GSA Board of Directors, said Dr. Dobi. I look forward to sharing the perspectives and concerns of early-career scientists with the Board, and to working with them to advance the field of genetics.

ABOUT GSA: Founded in 1931, the Genetics Society of America (GSA) is the professional membership organization for scientific researchers, educators, bioengineers, bioinformaticians and others interested in the field of genetics. Its nearly 5,000 members work to advance knowledge in the basic mechanisms of inheritance, from the molecular to the population level. The GSA is dedicated to promoting research in genetics and to facilitating communication among geneticists worldwide through its conferences, including the biennial conference on Model Organisms to Human Biology, an interdisciplinary meeting on current and cutting edge topics in genetics research, as well as annual and biennial meetings that focus on the genetics of particular organisms, including C. elegans, Drosophila, fungi, mice, yeast, and zebrafish. GSA publishes GENETICS, a leading journal in the field and an online, open-access journal, G3: Genes|Genomes|Genetics. For more information about GSA, please visit http://www.genetics-gsa.org. Also follow GSA on Facebook at facebook.com/GeneticsGSA and on Twitter @GeneticsGSA.

Go here to see the original:
Early Career Scientists Will Advise Genetics Society of America's Board

Recommendation and review posted by Bethany Smith

SAN MARINO, Calif.--(BUSINESS WIRE)--

Viral Genetics, Inc. (OTC Pink: VRAL) today announced that it has changed its name to VG Life Sciences Inc. and that it has completed its 1-for-600 reverse stock split, both of which will take effect at the open of trading on November 27, 2012. As of November 27, 2012, shares of the Companys common stock will begin trading on a split-adjusted basis on the OTC Pink market under the symbol VRAL with the fifth character D added to the end of the trading symbol for a period of 20 business days after November 27, 2012 to indicate the reverse stock split has occurred. Thereafter, the Companys symbol will revert to its original symbol VRAL until January 10, 2013. Effective January 10, 2013, a new ticker symbol for the Company will be announced and thereafter will take effect.

As previously disclosed, on November 27 every six hundred shares of outstanding Viral Genetics, Inc. common stock will be automatically combined into one share of VG Life Sciences Inc. common stock without any change in the par value per share. This change reduced the number of outstanding shares of common stock from approximately 1.9 billion to approximately 3.2 million. No fractional shares were issued in connection with the reverse stock split.

About VG Life Sciences Inc.

San Marino, California-based VG Life Sciences Inc., formerly known as Viral Genetics, discovers and develops drug therapies from two exclusively licensed platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar on Stage III and IV ovarian cancer patients is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. Founded in 1994, the biotech company is researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS. For more information, visit http://www.viralgenetics.com.

About VG Energy

VG Energy, Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of VG Life Sciences Inc. VG Energy holds the exclusive worldwide license to the Metabolic Disruption Technology (MDT) patent rights for use in the increase of production of various oils from algae, plants and seeds. VG Energys pivotal discoveries are expected to facilitate the biofuel industry in overcoming its major obstacle in the area of production efficiency, thereby leading to an increase in production yields that generate economically viable returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit http://www.vgenergy.net.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences Inc. from time to time in its periodic reports, including statements about its subsidiary, VG Energy, Inc. None of VG Life Sciences Inc.s drug compounds are currently approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While VG Life Sciences Inc. believes that the forward-looking statements and underlying assumptions are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of VG Life Sciences Inc. to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences Inc. will be achieved. VG Life Sciences Inc. disclaims any obligation to update these forward-looking statements, except as required by law.

Read the rest here:
Viral Genetics, Inc. Announces Corporate Name Change to VG Life Sciences Inc. and Reverse Stock Split Effective ...

Recommendation and review posted by Bethany Smith

Newswise The Genetics Society of America (GSA) welcomes six new members elected by the general membership to the 2013 GSA Board of Directors. The new members include a vice president, secretary and four directors. They are: Vicki L. Chandler, PhD (Gordon and Betty Moore Foundation). Dr. Chandler will serve as vice president in 2013 and as GSA president in 2014. Anne M. Villeneuve, PhD (Stanford University School of Medicine). Dr. Villeneuve will serve as secretary beginning 2013. Lynn Cooley, PhD (Yale University), director. Anna Di Rienzo, PhD (University of Chicago), director. Sarah C. R. Elgin, PhD (Washington University in St. Louis), director. Deborah A. Siegele, PhD (Texas A&M University), director.

As always, GSA is fortunate to be able to call upon such talented individuals to provide leadership for the Society, said GSA Executive Director Adam P. Fagen, PhD. As we welcome these new leaders, we thank the outgoing Board members for their years of dedicated service to GSA,

These new officers and directors began their tenure on January 1, 2013, and will remain on the GSA Board until December 31, 2015.

New Members of the GSA Board of Directors

Vice President (and President-Elect): Vicki L. Chandler, PhD, Chief Program OfficerScience, Gordon and Betty Moore Foundation, Palo Alto, CA.

Dr. Chandler is a plant geneticist and a long-time GSA member, who has served as an editor of the GSA journal GENETICS and as a member of the GSA Board in the 1990s. Her research on paramutation, an epigenetic process, has implications not only for maize, which she used in her research, but also for animal and human genetics and genetic diseases. For most of the last decade, Dr. Chandler has built bridges between the genetic worlds of plants and animals and developed a number of lasting scientific partnerships. From 2004-2009, she was director of the BIO5 Institute, an interdisciplinary research center at the University of Arizona, while her own lab worked on maize and other plants as models of genetic effects and applied findings to the study of human biology. At the Gordon and Betty Moore Foundation, Dr. Chandler helps foster scientific partnerships and the development of new technologies. In her new role as Vice President of GSA, she says, GSA has an obligation to communicate through public outreach and education, advances in genetics that offer significant potential improvements in health, energy, food and the environment, but also raise personal and social issues. Dr. Chandler is a member of the National Academy of Sciences and a Fellow of the American Association for the Advancement of Science; she is also a Searle Scholar and Presidential Young Investigator and received a National Institutes of Health (NIH) Directors Pioneer Award. Dr. Chandler served as president of the American Society of Plant Biologists in 2002.

Secretary: Anne M. Villeneuve, PhD, Professor of Developmental Biology and Genetics, Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA.

A developmental geneticist, Dr. Villeneuve studies the mechanisms of chromosome inheritance in eukaryotes during meiosis, using the nematode worm C. elegans for much of her work. She has been a member of GSA for many years and has participated in many GSA-sponsored conferences, has served as an associate editor of GENETICS, and has published some of her most influential articles in the Journal. She has an abiding, vested interest in promoting and sustaining the crucial mission of GSA, which includes being an advocate for support of basic science research and continued government support for crucial resources such as the genetics stock centers and databases that are essential to sustain ongoing research. She received a Junior Faculty Scholar Award from the Howard Hughes Medical Institute and was named a Searle Scholar.

Directors: Lynn Cooley, PhD, C.N.H. Long Professor of Genetics; Professor of Cell Biology and Molecular, Cellular & Developmental Biology, Yale University, New Haven, CT.

Dr. Cooley studies egg development or oogenesis, using the fruit fly Drosophila melanogaster as a model system. Specifically, her lab focuses on the cellular mechanisms controlling egg growth, which, according to her laboratory website, are directly relevant to female fertility in other animals, including humans. She is an associate editor of the GSA journal GENETICS, and has been a member of GSA for many years. She is also an active member of the Drosophila genetics community, including serving as an organizer for the GSA-sponsored Annual Drosophila Research Conference in 2009. As a member of the GSA Board of Directors, Dr. Cooley is looking forward to supporting GSAs incredibly important advocacy effort to maintain government support for basic research in these times of tight federal budgets. She received a Damon RunyonWalter Winchell Cancer Fund Postdoctoral Fellowship and was named a Pew Scholar in the Biomedical Sciences.

See the original post here:
Genetics Society of America Welcomes 2013 Board Members

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology Company, are conducting the ALCANZA trial, a phase III clinical trial of ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS is not approved for the treatment of CTCL.

This orphan drug designation is a part of our ADCETRIS regulatory strategy, designed to complement the Special Protocol Assessment for the ongoing ALCANZA study, said Clay B. Siegall, President and Chief Executive Officer of Seattle Genetics. The encouraging data from investigator-sponsored trials of ADCETRIS in CTCL, which will be presented at ASH, provide further support for our activities in this patient population.

FDA orphan drug designation is intended to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States. This designation provides Seattle Genetics with the opportunity for seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee.

The ALCANZA trial is a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The primary endpoint of the study is overall response rate lasting at least 4 months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the FDA. The study also received European Medicines Agency scientific advice. For more information about the ALCANZA trial, visit http://www.clinicaltrials.gov.

At the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA, data from two investigator-sponsored trials of ADCETRIS in CTCL will be reported:

Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression (Abstract #797)

Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30-positive cutaneous T-cell lymphomas and lymphoproliferative disorders (Abstract #3688)

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

More here:
Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides

Recommendation and review posted by Bethany Smith

FATAL FAMILIAL INSOMNIA BIO PSA
The question for my presentation that I was looking for an answer to was "What treatments have been discovered to fight or cure Fatal Familial Insomnia?" In my research I found that there has been some treatments tested on mice models that have slowed down the deadly disease, but researchers have not found one that will completely cure or sufficiently fight Fatal Familial Insomnia. In my discussion I talk about when the disease was discovered and how rare it is. I also explain what a prion disease is and codon is being effected. I have a chart in my presentation that compares the different sleep spindles, normal sleep vs. FFI sleep, so that the viewer can understand how extremely different a person with FFI sleep stages are to some one with normal sleep functions. The majority of my presentation was focused on the treatments section in which I list the tested treatments, some examples of cases that I found, and whether they made a difference or not. I found out that sleeping medications are the least successful in helping patients with FFI and can actually worsen the condition. Gene therapy as we discussed in the course already is the replacement of a mutated gene with a repaired one. The findings from the gene therapy case and agomelatine case showed that they are a helpful treatment, but not the cure to FFI. Even though these treatments did not work sufficiently to cure FFI, I think they are leading the researchers in the right direction to actually find the cure.From:DMarie23ifyViews:0 0ratingsTime:05:23More inPeople Blogs

Continued here:
FATAL FAMILIAL INSOMNIA BIO PSA - Video

Recommendation and review posted by Bethany Smith

Ahead of a planned five-centre nationwide trial, the Indian Council of Medical Research (ICMR) has approved a special project at the AIIMS Trauma Centre in New Delhi where stem cell therapy will be conducted on complete paraplegics and quadriplegics to try and revive limb function.

A similar trial will be conducted at the Indian Spinal Injuries Centre (ISIC) in Vasant Kunj, south-west Delhi where 21 patients have already been registered. This project too has been approved by the ICMR.

Senior ICMR scientists from the apex committee to monitor stem cell research said the five-centre trial will be coordinated from ISIC and is in the final stages of approval.

This will be the first national ICMR trial of autologous bone marrow stem cell transplant on complete quadriplegics and paraplegics. We are finalising the number of patients. The ISIC will be the coordinating centre. The next meeting has been scheduled for December 4, a senior scientist said.

An autologous stem cell transplantation is a procedure in which stem cells are removed, stored and returned to the same person.

For its project, the AIIMS Trauma Centre has registered eight patients. They will be injected with stem cells from their own bone marrow to see if the damaged neurological function can be regenerated. Doctors have cautioned that earlier trials on incomplete quadriplegics and paraplegics have not suggested significant clinical improvement.

Dr Deepak Aggarwal, associate professor of neurosurgery at the AIIMS Trauma Centre who is coordinating the study, said: We have necessary clearances from our internal ethics committee and the national apex committee for stem cell research and therapy which has members from the ICMR and Department of Biotechnology.

... contd.

Read the original post:
Two Delhi centres ready to try stem cell therapy on paraplegics

Recommendation and review posted by simmons

November 25, 2012 12:54

Former bassist is said to be still in a "partially conscious state" four years on from car accident

Photo: Tom Oxley/NME

Former Deftones bassist Chi Cheng's family are considering stem cell therapy to aid his recovery from a car accident which put him in a coma in 2008.

Cheng is said to be in a "partially conscious state" and is unable to speak, although he can move his legs on command. The bassist has been in and out of hospitals over the past four years and only got home to recover in June this year.

Now, according to Revolver Magazine, the family is considering alternative therapy in order to speed up Cheng's recovery, as they say the last few months have been a struggle for him.

His brother, Ming Cheng, said: "Once his health gets a little better, we'll start looking into other options... but they don't even do it [stem cell therapy] in the US yet.

"It's a miracle he's still with us," he added. "He's alive and kicking and he's fighting, and I think there's a reason for it. I'm hoping there's a light at the end of the tunnel for Chi."

Deftones released their new album 'Koi No Yokan' on November 12. You can stream the new record, which features 'Entomb (Dazzle)', 'Swerve City', 'Graphic Nature', 'Goon Squad' and 'Leathers', below.

The band tour the UK in 2013. They will play five dates, kicking off at Glasgow's Barrowland on February 15, before heading to Nottingham, Manchester, Birmingham and finishing at London's 02 Brixton Academy (20).

Original post:
Deftones' Chi Cheng's family consider stem cell therapy to aid recovery

Recommendation and review posted by simmons

NEW YORK, Nov. 26, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that Company management has been invited to present at the Piper Jaffray 24th Annual Healthcare Conference.

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Go here to read the rest:
NeoStem to Present at Piper Jaffray 24th Annual Healthcare Conference

Recommendation and review posted by simmons

Dell Powers Genomics Research Computing at SC12
In this video, Glen Otero from Dell discusses his Birds of Feather session on Personalized Medicine at SC12. The company is working with researchers to enable faster, more cost-effective genome sequencing to enable better healthcare for us all. Learn more at: sc12.supercomputing.org and content.dell.comFrom:RichReportViews:0 0ratingsTime:04:05More inScience Technology

The rest is here:
Dell Powers Genomics Research Computing at SC12 - Video

Recommendation and review posted by sam

The Future of Health IT: Episode 11
Todd Stottlemyer, CEO of Acentia discusses transformative legislation that will affect the future of Health IT, company culture at Acentia, the rise of personalized medicine, data analytics and mobility, and addresses the looming fiscal cliff. Also featured Jim McCarthy, Principal of AOC Key Solutions and "When to Walk Away"From:ksigcwViews:0 0ratingsTime:28:32More inNews Politics

Link:
The Future of Health IT: Episode 11 - Video

Recommendation and review posted by sam

Karting With The Stars 11/10/2012
Karting with the Stars event at Orlando Karting Center for SCI drivers. Event was was a huge success and was to help support GOSCIN (Greater Orlando Spinal Cord Injury Network) special thanks to Orlando Karting Center, Disability Wellness Center and all other sponsors for making this possible!From:Scott DarrowViews:0 0ratingsTime:13:49More inSports

Read more:
Karting With The Stars 11/10/2012 - Video

Recommendation and review posted by sam

The Moto | Inside The Outdoors | 2012 Episode #2 HD
PLEASE READ! As some of you may have heard one of our top Amateur riders Jantz Grodzicki was involved in a life threatening crash on Friday at this years Amateur Championship the Mini O #39;s. His injuries included a traumatic brain injury and a severed spinal cord at the base of his skull. It has been very touch and go over the last few days for the sixteen-year-old rider. At one point even though he was pronounced brain dead when he arrived at the Hospital the doctors were all amazed that at 6am Saturday morning he started to respond to certain commands with his eyes. As we all hoped that this was going to be one of many miracles that would spare this young mans life. Once again we received devastating news. Here are a few statements from his father Chris Grodzicky, Satuday Morning: "I wanted to first thank everyone for the heartfelt prayers for Jantz. I need to ask everyone the favor of including Jantz in your prayers as we move through this painful journey. Jantz sustained a devastating brain cell and spinal cord injury. He was wearing a neck brace and a top helmet. We left the hospital last night with zero hope from the doctors of his survival chances. His heart stopped at the track and he was pronounced brain dead at the hospital with no response. He was however put on life support until we decided on the options available that I hope none if you ever half to face. A short while ago we received a call from the doctor that a miracle took place this morning at 6:30am that ...From:CBMRACING972Views:997 14ratingsTime:20:28More inSports

Go here to read the rest:
The Moto | Inside The Outdoors | 2012 Episode #2 HD - Video

Recommendation and review posted by sam

RIP Jantz Grodzicki - Tribute - MX For Life
RIP Bravery Jantz GrodzickI - MX For Life This is Chris, Jantz #39;s dad... I wanted to first thank everyone for the heartfelt prayers for Jantz. I need to ask everyone the favor of including Jantz in your prayers as we move through this painful journey. Jantz sustained a devastating brain cell and spinal cord injury. He was wearing a layete brace and shoei helmet. We left the hospital last night with zero hope from the doctors of his survival chances. His heart stopped at the track and he was pronounced brain dead at the hospital with no response. He was however put on life support until we decided on the options available that I hope none if you ever half to face. A short while ago we received a call from the doctor that a miracle took place this morning at 6:30am that Jantz #39;s "condition has changed significantly" he is responding to eye commands, left to right, up and down and raise your eyebrows. Still no other responses other than this. Given what we were told this is truly a miracle. The thoughts and prayers shared here and on Facebook are what have helped him to make a move off the line. The race for recovery is just beginning and we can only pray that God will pull him through. May god bless each of you and your families. The Grodzicki Family....From:huntghostsViews:2072 26ratingsTime:01:12More inAutos Vehicles

Here is the original post:
RIP Jantz Grodzicki - Tribute - MX For Life - Video

Recommendation and review posted by sam

doctorb1 2012 05 20 sanda davis transfer RO 05jun 3c9ca2 transfer ro 29sep 53ee3e 1
Prime time tv Show on 20th may 2012 in Bucharest Romania, filmed in studio. Guests: me, Sanda Davis and Laura Ionescu patient recovering from spinal cord injury related paralisys. Producer/Director Daniela Lungu, directed and produced this second show with my story on B1TV. A third show will follow in June. You can see it here as well.From:Sanda DavisViews:0 0ratingsTime:20:30More inPeople Blogs

See the original post here:
doctorb1 2012 05 20 sanda davis transfer RO 05jun 3c9ca2 transfer ro 29sep 53ee3e 1 - Video

Recommendation and review posted by sam

RIP Jantz Grodzicki Tribute
My thoughts go out to the Friends and family of Jantz Grodzicki. Jantz sustained a devastating brain cell and spinal cord injury this past week at the Mini O #39;s in florida. He will be missed dearly. RIP Jantz Grodzicki #96From:Josh SmelserViews:2 0ratingsTime:01:42More inSports

Here is the original post:
RIP Jantz Grodzicki Tribute - Video

Recommendation and review posted by sam

Thanksgiving 2012 with Lester von Lahr and family
Les always cooked the Thanksgiving dinner and this was his first time at cooking Thanksgiving dinner since his spinal cord injury Dec. 1 2011. http://www.movingforwardinhope.com or facebook at moving forward in hope with Lester von LahrFrom:MovingForwardinHopeViews:0 0ratingsTime:01:36More inPeople Blogs

Go here to read the rest:
Thanksgiving 2012 with Lester von Lahr and family - Video

Recommendation and review posted by sam

Group Project: A Case Study of a Spinal Cord
Group project for biology class!! Spinal Cord InjuryFrom:Jasmine LarkViews:0 0ratingsTime:09:33More inEducation

See the article here:
Group Project: A Case Study of a Spinal Cord - Video

Recommendation and review posted by sam

Introduction To Stem Cell Therapy For Parkinson #39;s And Alzheimer #39;s Diseases | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy projects so much potential and hope for patients of different illnesses. This is due to the unique characteristics of stem cells. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:5 1ratingsTime:03:51More inPeople Blogs

Go here to see the original:
Introduction To Stem Cell Therapy For Parkinson's And Alzheimer's Diseases | Stem Cell Malaysia - Video

Recommendation and review posted by Bethany Smith

Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy can take on various forms and choices. Due to the advent of technology, stem cell therapy using oral placenta stem cells is now available. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:3 1ratingsTime:05:23More inScience Technology

Read more:
Introducing Stem Cell Therapy Using Oral Placenta Stem Cells | Stem Cell Malaysia - Video

Recommendation and review posted by Bethany Smith

DWAH Stem Cell Therapy.
From:Dundas West AHViews:6 0ratingsTime:03:53More inPets Animals

View post:
DWAH Stem Cell Therapy. - Video

Recommendation and review posted by Bethany Smith

Perrin 410 Animal Hospital Stem Cell Therapy
From:perrin410Views:0 0ratingsTime:09:58More inPets Animals

Continue reading here:
Perrin 410 Animal Hospital Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith